News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
We now rank 3rd in pharmaceutical production by volume and 14th by value
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
Time to combine innovation, access and technology to deliver positive patient outcomes
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics RoboCell cell line automation platform
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
